Navigation Links
New venture explores frontiers of personalized medicine

Pharmaceuticals that seek out cancerous cells and deliver treatments to them; imaging techniques that can help doctors detect diseases before the physical signs begin to appear; and medicines that are tailor-made for individual patients, are within the sights of an exciting new Australian start-up venture.

Clarity Pharmaceuticals Pty Ltd is a new venture, which could lead to a revolution in the future of medical diagnosis and treatment.

To launch the company, Clarity has secured licences to technology developed by the University of Melbourne and the Australian Nuclear Science and Technology Organisation (ANSTO).

Dr Matt Harris, Managing Director of TM Ventures says the basis of Clarity Pharmaceuticals is exciting new compounds developed by scientists from ANSTO and the University of Melbourne for use in positron emission tomography (PET).

"PET is the fastest growing nuclear medicine modality. Whilst tests such as X-ray and MRI provide information on anatomy and structure, PET uses the movement of radiopharmaceuticals through the body to examine metabolic processes, such as heart and brain function in real time," he said.

"Based on foundational research undertaken by the University of Melbourne and ANSTO, Clarity Pharmaceuticals is the future of personalised medicine."

Research teams from both the University of Melbourne and ANSTO have developed new compounds that significantly improve the accuracy of PET imaging.

These compounds can also be used in treatment to target therapeutics to specific disease sites and then to accurately monitor how well that treatment is working.

"These agents are targeted to selectively illuminate diseased tissue. The new compounds have the potential to provide clinicians with valuable diagnostic information to guide, improve and assess treatment regimes," said Dr Paul Donnelly from the University of Melbourne's School of Chemistry.

"Using PET images, doctors will have the potential to improve diagnosis and provide a personal prognosis. Ongoing monitoring using PET will determine progress and enable the refining of treatment options," he said.

According to ANSTO General Manager of Business Development, Rosanne Robinson, this exciting venture will enable even wider community accessibility to PET technology with great outcomes.

"For patients with cancer, this treatment could be revolutionary. No longer would patients suffer from the terrible side effects of chemotherapy because treatment could be precise, targeted and effective," she said.

In addition, the high calibre of research from which Clarity Pharmaceuticals has been founded, was acknowledged by the Victorian Government through the awarding of a Victoria Fellowship to a member of Dr Donnelly's research team, Dr Michelle Ma.


Contact: Rebecca Scott
University of Melbourne

Related medicine news :

1. Online Deals on Golf, now in Full Swing at
2. Win A Trip To New Zealand For Four: The Great Kiwi Adventure and ZESPRI's Kiwi A-Go-Go Bloggers' Contest
3. Abbey Color Inc. and Mexicana de Extractos International, S.A. de C.V. Announce Joint Venture Abbymex
4. Bold Ventures Launches New Healthcare Business
5. Kid Structures Prepares Houston's Beach Family for New Adventures
6. Iowan Tackles Everest and More in Unprecedented Adventure
7. Restless Josie, an Internet Adventure Travel Show, Empowers and Enlightens!
8. and Mike “Zappy” Zapolin Have Been Selected to Compete in Harvard Business School New Venture Contest
9. 15 Free Videos, Kids Visit GarGar The Dentist, Promote Children's Oral Health Education - MouthWise Web Adventures 4 Kids.
10. Forest City Announces Joint Venture with Health Care REIT for University Park Life Science Properties
11. Travel to 10 Best Eco-Adventure Destinations in India with Thrillophilia
Post Your Comments:
(Date:6/24/2016)... ... June 24, 2016 , ... June 19, 2016 is ... associated with chronic pain and the benefits of holistic treatments, Serenity Recovery Center ... suffering with Sickle Cell Disease. , Sickle Cell Disease (SCD) is a disorder of ...
(Date:6/24/2016)... ... 2016 , ... Global law firm Greenberg Traurig, P.A. announced that 20 Florida ... their peers for this recognition are considered among the top 2 percent of lawyers ... as members of this year’s Legal Elite Hall of Fame: Miami Shareholders Mark ...
(Date:6/24/2016)... ... ... of Topricin and MyPainAway Pain Relief Products, join The ‘Business for a Fair Minimum Wage’ ... 2020 and then adjusting it yearly to increase at the same rate as the median ... floor does not erode again, and make future increases more predictable. , The company is ...
(Date:6/24/2016)... ... June 24, 2016 , ... The Haute ... Dr. Barry M. Weintraub as a prominent plastic surgeon and the network’s newest ... world, and the most handsome men, look naturally attractive. Plastic surgery should be ...
(Date:6/24/2016)... ... ... National recruitment firm Slone Partners is pleased to announce the ... as Vice President of North American Capital Sales at HTG Molecular . ... team in the commercialization of the HTG EdgeSeq system and associated reagents in North ...
Breaking Medicine News(10 mins):
(Date:6/23/2016)... Calif. , June 23, 2016 ... CST on Thursday, July 7, 2016 , , , , ... ) , , , , EXPERT PANELISTS:  , , ... Naik; Senior Industry Analyst, Christi Bird; Senior Industry Analyst, Divyaa Ravishankar ... The global pharmaceutical industry is witnessing an exceptional ...
(Date:6/23/2016)... 23, 2016  Astellas today announced the establishment of Astellas Farma Colombia (AFC), a new affiliate with operations headquartered ... Latin America . ... ... ... ...
(Date:6/23/2016)... 2016  Guerbet announced today that it has been ... Award . One of 12 suppliers to ... its support of Premier members through exceptional local customer ... commitment to lower costs. ... our outstanding customer service from Premier," says Massimo ...
Breaking Medicine Technology: